Multiple Sclerosis Centers of Excellence
Disease Modifying Therapies for Multiple Sclerosis
Treatments for MS focus on controlling the immune system and managing symptoms. The current goals for MS care are to reduce the frequency of relapses and to slow the progression of the disease by using a drug therapy approach called disease modifying treatments (DMTs). In addition to the use of a DMT, it is important for people to work with their health care providers to find the best approach to address MS symptoms like extreme fatigue, bladder problems, and muscle spasms. MS symptoms can be managed with conventional medication, complementary and alternative medicine, physical therapy, mobility devices, and other self-care approaches.
The links below go to the National MS Society webpages for the DMTs. Information on medications can also be found on the National MS Society medications webpage.
Injected DMTs
- Avonex (Interferon Beta-1a)
- Betaseron (Interferon Beta-1b)
- Copaxone (Glatiramer Acetate)
- Extavia (Interferon Beta-1b)
- Glatiramer Acetate Injection (generic equivalent of Copaxone)
- Glatopa (generic equivalent of Copaxone)
- Kesimpta (Ofatumumab)
- Ocrevus Zunovo
- Plegridy (Peginterferon Beta-1a)
- Rebif (Interferon Beta-1a)
Oral DMTs
- Aubagio (Teriflunomide)
- Bafiertam (Monomethyl Fumarate)
- Dimethyl Fumarate (generic equivalent of Tecfidera)
- Gilenya (Fingolimod)
- Mavenclad (Cladribine)
- Mayzent (Siponimod)
- Ponvory (Ponesimod)
- Tascenso ODT (Fingolimod)
- Tecfidera (Dimethyl Fumarate)
- Vumerity (Diroximel Fumarate)
- Zeposia (Ozanimod)
Infused DMTs
- Briumvi (Ublituximab)
- Lemtrada (Alemtuzumab)
- Novantrone (Mitoxantrone)
- Ocrevus (Ocrelizumab)
- Tyruko (Natalizumab-sztn)
- Tysabri (Natalizumab)
Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.
